IDentif.AI-Optimized Drug Combinations to Restore COVID-19 Antibody Potency

63.0 KB of data from an AI-driven platform (IDentif.AI) used to identify synergistic drug combinations for COVID-19 treatment. The study, authored by Peter Wang, aimed to resurrect the potency of the antibody sotrovimab against the XBB variant. Results indicate combinations that reduced the in vitro EC50 of sotrovimab by up to 7-fold.

Use Cases

• Training AI models for drug synergy prediction based on in vitro efficacy data.
• Analyzing dose-response relationships for antibody-drug combinations mentioned in the description.
• Benchmarking combination optimization platforms using the IDentif.AI methodology described.

Strengths

• Data is associated with a specific, peer-reviewed scientific method (IDentif.AI platform).
• Results include a concrete, quantified efficacy improvement (7-fold EC50 reduction).
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• Row count and column-level documentation are absent, requiring manual inspection after download.
• The 63.0 KB file size suggests a limited scope, likely containing summary or experimental results rather than large-scale raw data.
• Data freshness should be verified, as the last update is listed as 2026-06-02.

Provenance

Source

figshare, author Peter Wang.

Collection Method

Generated via the IDentif.AI artificial intelligence platform for drug combination optimization.

Time Range

Study context focuses on the XBB variant, which was predominant worldwide in 2023.

Freshness

Last updated 2026-06-02 05:26:40.